BAM
PCRX icon

Blueshift Asset Management’s Pacira BioSciences PCRX Stock Holding History

Blueshift Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,710
Closed -$376K – 1138
2021
Q3 		$376K Sell
6,710
-5,671
-46% -$327K 0.02% 732
2021
Q2 		$751K Buy
12,381
+6,176
+100% +$391K 0.04% 433
2021
Q1 		$435K Buy
6,205
+1,477
+31% +$106K 0.04% 516
2020
Q4 		$283K Buy
+4,728
New +$277K 0.03% 539
2019
Q3 		– Sell
-4,914
Closed -$214K – 902
2019
Q2 		$214K Buy
+4,914
New +$209K 0.03% 638

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Blueshift Asset Management's PCRX Position: Q4 2021 in Review

Blueshift Asset Management sold out of Pacira BioSciences (PCRX) in Q4 2021, closing a stake of 6,710 shares — an estimated $376K sold.

Blueshift Asset Management first reported a position in PCRX in Q2 2019 and held it in 5 quarters. The position peaked at $751K in Q2 2021. 276 funds tracked by Wall St. Rank hold PCRX as of Q4 2021.

  • Blueshift Asset Management reported no remaining Pacira BioSciences position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 6,710 Pacira BioSciences shares in Q4 2021, an estimated $376K.
  • Blueshift Asset Management first reported a position in Pacira BioSciences in Q2 2019 and held it in 5 quarters.
  • Blueshift Asset Management's Pacira BioSciences position peaked at $751K in Q2 2021.
  • 276 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.